Manufacturer or GPO Program year 2023 Source: CMS Open Payments

Pfizer Limited

Great Britain (UK)

CMS manufacturer 100000000323

Open in the dashboard

General payments

$62,745

16 payments

Research payments

$0

0 payments

Ownership & investment interest

$0

None reported

Through program year 2023, Pfizer Limited reported paying $62,745 in general payments and $0 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2023 General $22,572 10
2022 General $18,867 4
2021 General $206 1
2019 General $21,100 1

Breakdown

Top recipients General payments · program year 2023
  1. Rajender Reddy Internal Medicine · Hammonton, NJ $10,406 4 payments
  2. Barbara Konkle Hematology · Seattle, WA $10,149 4 payments
  3. Steven Deitelzweig Internal Medicine · New Orleans, LA $2,017 2 payments
Products the payments named General payments · program year 2023
  1. Xyntha Hematology $20,555 48% · 2 recipients
  2. Benefix Hematology $20,555 48% · 2 recipients
  3. Eliquis Cardiovascular;Metabolic Disease $2,017 5% · 1 recipient

Each share is of this company’s general payments naming a product in 2023. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2023
  1. Internal Medicine $12,423 55% · 2 practitioners
  2. Hematology Internal Medicine $10,149 45% · 1 practitioner

Each share is of this company’s general payments to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2023
  1. New Jersey $10,406 46% · 1 recipient
  2. Washington $10,149 45% · 1 recipient
  3. Louisiana $2,017 9% · 1 recipient

Each share is of this company’s general payments in 2023 where a state was reported.

What the payments were for General payments · program years 2019–2023
  1. Travel and Lodging $39,582 12 payments
  2. Royalty or License $21,100 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,063 3 payments
Companies with a similar name General payments · program years 2019–2023
  1. Pfizer Inc. NY, United States $513,229,393
  2. Pfizer International LLC NY, United States $1,402,022
  3. Pfizer Pharmaceuticals LLC PR, United States $201,484
  4. Pfizer Chile S.A. Chile $78,355
  5. Pfizer S.A.S. Colombia $19,741
  6. Pfizer S.A. Peru $18,543
  7. Pfizer Canada Inc Canada $2,036
  8. Pfizer Pharma GMBH Germany $2,030
  9. Pfizer Zona Franca, S.A. Costa Rica $1,395
  10. Pfizer Corporation Hong Kong Limited Hong Kong $653

Grouped by name only. CMS publishes no corporate ownership, so a shared name does not mean a shared parent. The largest 10 of 13.

16 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record